Gingko Bioworks and Merck Ink Collaboration Deal over Biocatalytic Enzymes
Gingko Bioworks and Merck have inked a collaboration deal to develop Gingko’s biocatalytic enzymes for potential use in Merck’s drug manufacturing processes.
Under the terms of the deal, up to four enzymes can be engineered for use as biocatalysts in Merck’s active pharmaceutical ingredient manufacturing efforts.
Biocatalysis — the use of living systems or their parts to speed up chemical reactions — is an alternative to some chemical synthesis steps in industrial chemical synthesis, which is sustainable and often more effective, Gingko said.
No upfront payment was disclosed, but Gingko is eligible to receive up to $144 million in commercial milestone payments.